China Pharma Holdings EBIT

China Pharma Holdings (CPHI) currently reports a EBIT of $-6T as of March 2026. That compares with $-3.2T in the prior-year period — down 85.2% year over year. That is below the Healthcare sector average of $22B. Use the charts on this page to explore China Pharma Holdings's EBIT history and peer comparisons.

China Pharma Holdings's EBIT decreased from $-3.2T to $-6T — a 85.2% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

China Pharma Holdings's EBIT of $-6T is lower than the Healthcare sector average of $22B. That is roughly 26832.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

China Pharma Holdings reported $-6T in EBIT as of March 2026. That compares with $-3.2T in the prior-year period — down 85.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-6T, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $22B. From there, open related valuation or income-statement pages for China Pharma Holdings, and consider following CPHI for alerts when major investors trade the stock.